Skip to content

Characterization of Enterococci

Characterization of Enterococci; Distribution of Virulence Markers, Virulence Genes and Antibiotic Resistance Pattern of the Isolated Species

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04777240
Enrollment
52
Registered
2021-03-02
Start date
2020-02-01
Completion date
2021-03-10
Last updated
2021-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Samples From Patients With Enterococcal Infections

Brief summary

Study on Characterization of Enterococci because nowadays it become an important cause of nosocomial infections .detection of the most common two species of Enterococci and most common virulence factors & its genes with determination of antibiotics sensitivity test for the isolated strains

Interventions

None listed

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
2 Months to 90 Years

Inclusion criteria

* any patients in ICU has manifestations of urinary tract infections, surgical wound infections, intra-abdominal infections, intrapelvic infections, bacteraemia and infective endocarditis

Exclusion criteria

* patients receiving antibiotics in previous 48 hours

Design outcomes

Primary

MeasureTime frameDescription
I) Sample collection2 monthsSamples are collected from intensive care unit (ICU) including urine, pus swabs, sputum, blood, tracheal aspirates and pharyngeal swabs
II) Identification of Enterococci:2 monthby inoculation on Bile esculin azide & growing colonies further identified by : 1. microscopically after staining by gram stain 2. catalase test 3. grow on high concentration of NaCl (6.5%)
III) Phenotypic detection of virulence marker of Enterococci(Gelatinase activity)2 weeksby culture on nutrient agar containing gelatin.Positive results appeared as liquefaction of gelatin
IV)Phenotypic detection of virulence marker of Enterococci (hemolytic activity)1 weekby Detection of hemolytic activity on the blood agar
V) Phenotypic detection of virulence marker of Enterococci(Caseinase production)2 weeksby Detection of Caseinase production on Muller hinton agar containing skimmed milk 3%.
VI) Phenotypic detection of virulence marker of Enterococci(Formation of Slime layer)1 weekFormation of Slime layer by culture on Brain heart infusion agar containing 5% sucrose, plates are incubated for 24 hrs at 37oC. Positive strains gave mucoid and slimy colonies.
VII) Phenotypic detection of virulence marker of EnterococcI (Biofilm formation)2 weeksusing microtiter plate reader. Biofilm formation is scored as nonbiofilm forming (-), weak - (+), moderate - (++), and strong - (+++) corresponding to the A630 values ≤1, 1-≤2, 2-≤3, and\>3, respectively
VIII) Antibiotic sensitivity test:3 monthe1. by 1- disc diffusion test using Vancomycin 30 μg, Teichoplanin 30 μg, Tetracycline 30 μg, Ampicillin 10 μg and Erythromycin 15 μg. Results ,Results are interpreted according to CLSI 2018. 2. E-test: MICs (minimal inhibitory concentrations) of Vancomycin are measured by E-test for confirmation of vancomycin resistance among the isolated Enterococci. Results are interpreted according to CLSI guidelines.
IX) Molecular Identification of commonest Enterococcus species1 monthby conventional gene specific uniplex PCR for E. faecalis and E. Faecium
X) Molecular detection of virulence genes2 monthsIdentification of virulence genes; gel E (gene for gelatinase), asa1 (gene for aggregation substance), cylA (gene for cytolysin activator), esp (gene for Enterococcal surface protein) Hyl (gene for Hyaluronidase) of E. faecalis and E. faecium was performed by uniplex PCR.The amplified products are visualized on 2% agarose gel stained with ethidium bromide. The stained gels are visualized and documented with a gel documentation system and analyzed visually to determine the size of PCR amplicons of the target genes directly by comparison with 100 bp DNA ladder marker.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026